PROVENTION BIO, INC.

PRVB
Delayed Nasdaq - 04:00 2022-11-30 pm EST
9.040 USD +2.96%

Turn to zoom
Prev.9.04000000
Open8.83000000
High9.20000000
Low8.78200000
Volume1 989 104
Latest news
11/21
11/21
11/21
11/18
Chart PROVENTION BIO, INC.
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBullish
Resistance9,509,509,50
Spread/Res.-4,8%-4,8%-4,8%
Spread/Supp.16%69%61%
Support7,775,355,62
Financials
Sales 2022 9,12 M - -
Net income 2022 -135 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,15x
Yield 2022 -
Capitalization 788 M 788 M -
Capi. / Sales 2022 86,5x
Capi. / Sales 2023 13,8x
Nbr of Employees 82
Free-Float 93,8%
Company
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on intercepting and preventing immune-mediated diseases. The Company's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody...
Sector :
Bio Therapeutic Drugs
Calendar :
2023-02-23 Earnings Release
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,04 $
Average target price 18,38 $
Spread / Average Target 103%